查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1668041

格林-巴利综合症诊断市场 - 全球产业规模、份额、趋势、机会和预测，按测试、最终用途、地区和竞争细分，2020-2030 年预测

Guillain-Barre Syndrome Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test, By End-use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球格林巴利症候群诊断市场价值为 1.5095 亿美元，预计到 2030 年将达到 1.7342 亿美元，预测期内复合年增长率为 5.12%。格林巴利症候群 (GBS) 是一种罕见但严重的神经系统疾病，人体的免疫系统错误地攻击週边神经系统，导致肌肉无力、麻木，严重时甚至会导致瘫痪。早期准确的诊断对于有效的管理和治疗至关重要，但该疾病的多变性和与其他神经系统疾病的重迭症状使其识别具有挑战性。

市场概况
预测期 2026-2030
2024 年市场规模 1.5095 亿美元
2030 年市场规模 1.7342亿美元
2025-2030 年复合年增长率 2.30％
成长最快的领域 腰椎穿刺
最大的市场 北美洲

诊断格林巴利症候群的第一步是进行详细的临床检查和了解病史。医生会评估肌肉无力的发生和发展情况，通常从下肢开始，然后向上身发展。反射通常会减弱或消失，这是格林-巴利症候群的显着特征。患者也可能报告感觉障碍，例如刺痛或疼痛，以及自主神经功能障碍，包括血压波动和心律不整。由于格林-巴利症候群常常由先前的感染引发，因此医生会询问近期的疾病，例如呼吸道感染或胃肠道疾病。

神经传导研究（NCS）和肌电图（EMG）是确认GBS的重要诊断工具。 NCS 测量週边神经中电讯号的速度和强度。在格林-巴利症候群中，这些讯号会因神经脱髓鞘或轴突损伤而减慢或受阻。 EMG 可以评估肌肉对神经刺激的反应，有助于区分 GBS 与其他神经肌肉疾病。这些测试的结果为 GBS 的亚型提供了宝贵的见解，例如急性发炎性脱髓鞘多发性神经病变 (AIDP) 或急性运动轴突性神经病变 (AMAN)。

通常会进行腰椎穿刺（脊椎穿刺）来分析包围大脑和脊髓的脑脊髓液（CSF）。在格林-巴利症候群中，脑脊髓液分析通常显示蛋白质水平升高而白血球没有显着增加，这种发现称为白蛋白细胞分离。然而，这种标誌性特征可能在疾病的早期阶段不存在，如果临床怀疑仍然很高，则需要重复检测。

主要市场驱动因素

格林-巴利症候群发生率上升

主要市场挑战

认识不足和误诊

主要市场趋势

诊断技术的进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球格林巴利症候群诊断市场的影响

第 5 章：全球格林巴利症候群诊断市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 透过检查（腰椎穿刺、肌电图、其他）
    • 依最终用途（医院和诊所、诊断实验室、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第 6 章：北美格林巴利症候群诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第 7 章：欧洲格林巴利症候群诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区格林-巴利症候群诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲格林巴利症候群诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲格林-巴利症候群诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 测试启动（如果有）
  • 最新动态

第 13 章：全球格林巴利症候群诊断市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen srl
  • Deymed Diagnostic sro
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft mbH
  • Rochester Electro-Medical, Inc.

第 16 章：策略建议

第17章 调査会社について・免责事项

简介目录
Product Code: 27713

Global Guillain-Barre Syndrome Diagnostics Market was valued at USD 150.95 Million in 2024 and is expected to reach USD 173.42 Million by 2030 with a CAGR of 5.12% during the forecast period. Guillain-Barre Syndrome (GBS) is a rare but serious neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, numbness, and in severe cases, paralysis. Early and accurate diagnosis is critical for effective management and treatment, but the condition's variability and overlapping symptoms with other neurological disorders make its identification challenging.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 150.95 Million
Market Size 2030USD 173.42 Million
CAGR 2025-20302.30%
Fastest Growing SegmentLumbar Puncture
Largest MarketNorth America

The first step in diagnosing GBS involves a detailed clinical examination and patient history. Physicians assess the onset and progression of muscle weakness, typically starting in the lower limbs and ascending toward the upper body. Reflexes are often diminished or absent, a hallmark characteristic of GBS. Patients may also report sensory disturbances, such as tingling or pain, and autonomic dysfunction, including blood pressure fluctuations and abnormal heart rhythms. Since GBS is often triggered by a preceding infection, doctors inquire about recent illnesses such as respiratory infections or gastrointestinal disturbances.

Nerve conduction studies (NCS) and electromyography (EMG) are essential diagnostic tools for confirming GBS. NCS measures the speed and strength of electrical signals in the peripheral nerves. In GBS, these signals are slowed or blocked due to nerve demyelination or axonal damage. EMG, which assesses muscle response to nerve stimulation, can help distinguish GBS from other neuromuscular conditions. The results of these tests provide valuable insights into the subtype of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) or acute motor axonal neuropathy (AMAN).

A lumbar puncture (spinal tap) is often performed to analyze cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. In GBS, CSF analysis typically reveals elevated protein levels without a significant increase in white blood cells, a finding known as albuminocytological dissociation. However, this hallmark feature may not be present in the early stages of the disease, requiring repeated testing if clinical suspicion remains high.

Key Market Drivers

Rising Incidence of Guillain-Barre Syndrome

Guillain-Barre Syndrome (GBS) is an autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. The global rise in the incidence of GBS has become a significant concern for healthcare providers, prompting increased demand for accurate and timely diagnostic solutions. The growing number of GBS cases worldwide, fueled by viral infections, vaccinations, and other autoimmune triggers, is a key driver of the expanding Guillain-Barre Syndrome diagnostics market. According to the National Organization for Rare Disorders (NORD), Guillain-Barre Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.

One of the major factors contributing to the rising incidence of GBS is the increased prevalence of viral infections such as Zika virus, cytomegalovirus, and Epstein-Barr virus, which have been linked to the onset of the syndrome. Additionally, seasonal influenza and COVID-19 infections have also been associated with a higher risk of developing GBS. The correlation between these infections and GBS has intensified the need for early and precise diagnostic tools, including cerebrospinal fluid (CSF) analysis, electromyography (EMG), and nerve conduction studies (NCS), which are essential for confirming GBS and differentiating it from other neurological disorders.

Advancements in diagnostic technologies are further propelling market growth. Innovations in biomarker detection, molecular diagnostics, and imaging techniques have enhanced the ability to identify GBS in its early stages, leading to improved patient outcomes. Additionally, artificial intelligence (AI)-driven diagnostic solutions are being developed to enhance the accuracy and efficiency of GBS detection. These technological advancements are helping to meet the growing demand for rapid and reliable diagnostic procedures, further expanding the market.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges in the GBS diagnostics market is the lack of awareness among healthcare providers and the general population. Guillain-Barre Syndrome presents with symptoms similar to other neurological disorders, such as multiple sclerosis and myasthenia gravis, leading to frequent misdiagnosis or delayed identification. This delay in diagnosis can significantly impact patient outcomes, as early intervention is critical in managing the condition effectively.

Key Market Trends

Technological Advancements in Diagnostics

One of the key trends shaping the GBS diagnostics market is the advancement in diagnostic technologies. Modern electrophysiological tests, such as NCS and EMG, are becoming more precise and efficient, aiding in the differentiation of GBS subtypes. Additionally, biomarker research has gained traction, with efforts focused on identifying specific autoantibodies and inflammatory markers that could improve the accuracy of GBS diagnosis. The integration of artificial intelligence (AI) and machine learning in medical imaging and electrophysiology has the potential to enhance diagnostic efficiency, reducing the time needed for clinical decision-making.

Key Market Players

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen s.r.l.
  • Deymed Diagnostic s.r.o.
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft m.b.H.
  • Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test:

  • Lumbar Puncture
  • Electromyography
  • Others

Guillain-Barre Syndrome Diagnostics Market, By End use:

  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Others

Guillain-Barre Syndrome Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Guillain-Barre Syndrome Diagnostics Market

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
    • 5.2.2. By End Use (Hospitals And Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test
        • 6.3.3.2.2. By End Use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test
        • 7.3.5.2.2. By End Use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test
        • 8.3.5.2.2. By End Use

9. South America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Guillain-Barre Syndrome Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Test Launches (If Any)
  • 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Cadwell Industries, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Natus Medical Incorporated
  • 15.3. Nihon Kohden Corporation
  • 15.4. Medtronic plc
  • 15.5. Bionen s.r.l.
  • 15.6. Deymed Diagnostic s.r.o.
  • 15.7. Neurosoft Ivanovo, Russia
  • 15.8. Alpine Biomedicals Pvt Ltd.
  • 15.9. EMS Handels Gesellschaft m.b.H.
  • 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer